Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Argentine bodies sign renal dialysis accreditation deal:

This article was originally published in Clinica

Executive Summary

Argentina has taken a significant step forward in extending the accreditation of its dialysis services. The national chamber of renal therapy services and products (CASPT) has entered an agreement with the institute for the accreditation of healthcare services (ITAES) to perform the testing. The success of the initiative will, however, depend on service providers coming forward for assessment. The regular testing regime undertaken by ITAES is voluntary and confidential. To date, six leading centres have been accredited, according to Fresenius Medical Care. ITAES is a non-governmental organisation set up by leading healthcare service providers, industry associations and healthcare funding bodies to conduct quality-assurance and biosecurity accreditation.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT057955

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel